Quarterly Result9 Feb 2026, 04:07 pm
Fermenta Biotech's 9MFY26 Revenue Surges 25% YoY, Net Profit Up 20% YOY
AI Summary
Fermenta Biotech Limited, a leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals, announced its consolidated revenue for the nine months ended 31 December 2025 was INR 421.2 crore, up 25% from the same year-ago period. The net profit for the same period was INR 51.7 crore, a 20% YoY increase. The growth was primarily driven by the strong performance of the Vitamin D3 - Human Nutrition segment.
Key Highlights
- Consolidated revenue for 9MFY26 was INR 421.2 crore, up 25% YoY.
- Net profit for 9MFY26 was INR 51.7 crore, up 20% YoY.
- Strong growth in Vitamin D3 - Human Nutrition segment.
- INR 110 crore capex approved at Dahej for plant-based Vitamin D3, green chemistry enzymes, and Vitamin D3 derivatives.
- One-time, exceptional expense of INR 2.19 crore towards employee benefits due to new Labour Codes.